ACW — Actinogen Medical Share News
0.000.00%
Last trade - 00:00- AU$146.60m
- AU$140.29m
- AU$0.69m
Brief: Actinogen Medical Completes A$16.8M Placement And Spp
Brief: Actinogen Medical To Raise A$12.0 Million
Brief: Actinogen Medical Seeks Trading Halt
Brief: Actinogen Randomizes 247th Patient in Xanamia Phase 2b/3 Alzheimer’s Trial
Brief: Actinogen Medical Receives Initial A$5.5M Research And Development Tax Incentive Rebate
Brief: Actinogen Reaches FDA Agreement on Xanamem Pathway for Future U.S. Alzheimer’s Approval in Type C Meeting
Brief: Actinogen Medical Confirms 100Th Participant In Xanamia Phase 2B/3 Alzheimer's Disease Trial And Interim Analysis Timeline
Brief: Actinogen Provides Pivotal Alzheimer’S Trial Enrolment Update
Brief: Actinogen Medical Acw Conducts Type C Meeting With FDA
Brief: Actinogen Medical Posts HY Net Loss Attributable A$8.2 Million
Brief: Actinogen Medical Says World Health Organization Granted Nonproprietary Name 'Emestedastat' To Co
Brief: Actinogen Randomizes First Us Participant In Xanamia Phase 2B/3 Alzheimer's Disease Trial
Brief: Actinogen Medical Says A$3.0 Mln Share Purchase Plan Closes
Australia's Actinogen Medical falls on discounted placement
Brief: Actinogen Medical Announces Launch Of A$3.0 Mln Share Purchase Plan
Brief: Actinogen Medical Seeks Trading Halt
Brief: Actinogen Medical Posts FY Net Loss Attributable A$13 Million
Brief: Actinogen Announces Further Positive Results In The Xancidd Phase 2A Trial
Brief: Actinogen Announces Superiority Of Xanamem® Over Placebo On Depression In Xanacidd Phase 2A Trial